Legislation just passed in Japan could accelerate Mesoblast's (MSB) entry into the largest market outside of the US

James Marlay

Livewire Markets

Legislation just passed in Japan could accelerate Mesoblast's (MSB) entry into the largest market outside of the US. The legislation, specifically for stem cell technologies, enables products to come to market without having to progress through critical phase 3 trials. The development could save Mesoblast years and millions of dollars in reaching the large Japanese market. Mesoblast's CEO, Silviu Itescu, says he is modeling the business on leading Nasdaq biotech companies and plans to commence four phase 3 trials this year. Having multiple trials running simultaneously, cash in the bank and major partners to share the risks are important factors in justifying Mesoblast's $2 billion valuation. In an interview on Inside Business, Silviu Itescu (CEO) discusses the accelerated pathways now available to certain technologies, the Nasdaq style model he is creating and how investors can value the business based on the pipeline of phase 3 trials. (VIEW LINK)


James Marlay
Co Founder
Livewire Markets

Livewire is Australia’s #1 website for expert investment analysis. We work with leading investment professionals to deliver curated content that helps investors make confident and informed decisions. Safe investing and thanks for reading Livewire.

Expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.